598 related articles for article (PubMed ID: 26188543)
1. Structural, morphological, and functional diversity of amyloid oligomers.
Breydo L; Uversky VN
FEBS Lett; 2015 Sep; 589(19 Pt A):2640-8. PubMed ID: 26188543
[TBL] [Abstract][Full Text] [Related]
2. Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange.
Carulla N; Zhou M; Giralt E; Robinson CV; Dobson CM
Acc Chem Res; 2010 Aug; 43(8):1072-9. PubMed ID: 20557067
[TBL] [Abstract][Full Text] [Related]
3. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation.
Lorenzen N; Nielsen SB; Buell AK; Kaspersen JD; Arosio P; Vad BS; Paslawski W; Christiansen G; Valnickova-Hansen Z; Andreasen M; Enghild JJ; Pedersen JS; Dobson CM; Knowles TP; Otzen DE
J Am Chem Soc; 2014 Mar; 136(10):3859-68. PubMed ID: 24527756
[TBL] [Abstract][Full Text] [Related]
4. Interpreting the aggregation kinetics of amyloid peptides.
Pellarin R; Caflisch A
J Mol Biol; 2006 Jul; 360(4):882-92. PubMed ID: 16797587
[TBL] [Abstract][Full Text] [Related]
5. Oligomers, protofibrils and amyloid fibrils from recombinant human lysozyme (rHL): fibrillation process and cytotoxicity evaluation for ARPE-19 cell line.
Ruiz ED; Almada M; Burboa MG; Taboada P; Mosquera V; Valdez MA; Juárez J
Colloids Surf B Biointerfaces; 2015 Feb; 126():335-43. PubMed ID: 25618793
[TBL] [Abstract][Full Text] [Related]
6. Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity.
Fändrich M
J Mol Biol; 2012 Aug; 421(4-5):427-40. PubMed ID: 22248587
[TBL] [Abstract][Full Text] [Related]
7. Computational studies of protein aggregation: methods and applications.
Morriss-Andrews A; Shea JE
Annu Rev Phys Chem; 2015 Apr; 66():643-66. PubMed ID: 25648485
[TBL] [Abstract][Full Text] [Related]
8. Structural remodeling during amyloidogenesis of physiological Nα-acetylated α-synuclein.
Gallea JI; Sarroukh R; Yunes-Quartino P; Ruysschaert JM; Raussens V; Celej MS
Biochim Biophys Acta; 2016 May; 1864(5):501-10. PubMed ID: 26845568
[TBL] [Abstract][Full Text] [Related]
9. Early mechanisms of amyloid fibril nucleation in model and disease-related proteins.
Morel B; Conejero-Lara F
Biochim Biophys Acta Proteins Proteom; 2019 Nov; 1867(11):140264. PubMed ID: 31437584
[TBL] [Abstract][Full Text] [Related]
10. Structure and Aggregation Mechanisms in Amyloids.
Almeida ZL; Brito RMM
Molecules; 2020 Mar; 25(5):. PubMed ID: 32155822
[TBL] [Abstract][Full Text] [Related]
11. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
13. Self-inhibition of insulin amyloid-like aggregation.
Ziaunys M; Sneideris T; Smirnovas V
Phys Chem Chem Phys; 2018 Nov; 20(43):27638-27645. PubMed ID: 30374505
[TBL] [Abstract][Full Text] [Related]
14. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
15. Defining the pathway of worm-like amyloid fibril formation by the mouse prion protein by delineation of the productive and unproductive oligomerization reactions.
Jain S; Udgaonkar JB
Biochemistry; 2011 Feb; 50(7):1153-61. PubMed ID: 21214263
[TBL] [Abstract][Full Text] [Related]
16. A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.
Faria TQ; Almeida ZL; Cruz PF; Jesus CS; Castanheira P; Brito RM
Phys Chem Chem Phys; 2015 Mar; 17(11):7255-63. PubMed ID: 25694367
[TBL] [Abstract][Full Text] [Related]
17. Structural Characteristics of α-Synuclein Oligomers.
Cremades N; Chen SW; Dobson CM
Int Rev Cell Mol Biol; 2017; 329():79-143. PubMed ID: 28109332
[TBL] [Abstract][Full Text] [Related]
18. Two-Step Amyloid Aggregation: Sequential Lag Phase Intermediates.
Castello F; Paredes JM; Ruedas-Rama MJ; Martin M; Roldan M; Casares S; Orte A
Sci Rep; 2017 Jan; 7():40065. PubMed ID: 28067252
[TBL] [Abstract][Full Text] [Related]
19. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses.
Zhang X; Sun XX; Xue D; Liu DG; Hu XY; Zhao M; Yang SG; Yang Y; Xia YJ; Wang Y; Liu RT
Biochim Biophys Acta; 2011 Dec; 1814(12):1703-12. PubMed ID: 21979582
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of lysozyme amyloid cytotoxicity by SPION-mediated modulation of amyloid aggregation.
Naik A; Kambli P; Borana M; Mohanpuria N; Ahmad B; Kelkar-Mane V; Ladiwala U
Int J Biol Macromol; 2015 Mar; 74():439-46. PubMed ID: 25562831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
